相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman et al.
LANCET (2021)
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis
Niranjan J. Sathianathen et al.
EUROPEAN UROLOGY (2020)
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
Justin Ferdinandus et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option
Nikhil Mayor et al.
BJU INTERNATIONAL (2020)
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
Bastiaan M. Prive et al.
BMC CANCER (2020)
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
Wolfgang P. Fendler et al.
CLINICAL CANCER RESEARCH (2019)
TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Michael S. Hofman et al.
BJU INTERNATIONAL (2019)
Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics
Declan G. Murphy et al.
EUROPEAN UROLOGY (2019)
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
Sue Ping Thang et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol
Michael S. Hofman et al.
BJU INTERNATIONAL (2018)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Richard P. Baum et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer
Matthias M. Heck et al.
JOURNAL OF UROLOGY (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
Hojjat Ahmadzadehfar et al.
ONCOTARGET (2016)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
Hojjat Ahmadzadehfar et al.
EJNMMI RESEARCH (2015)
WIDEN: A tool for medical image management in multicenter clinical trials
Stephane Chauvie et al.
CLINICAL TRIALS (2014)
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
A Ghosh et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy
N Schülke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
